Fingolimod Hydrochloride

DRUG3 trials

Sponsors

Novartis Pharma AG, Mayo Clinic

Conditions

Breast CarcinomaChemotherapy-Induced Peripheral NeuropathyMultiple Sclerosis in pediatric patientsNumbnessPainTingling

Early Phase 1

Fingolimod in Treating Patients With Chemotherapy-Induced Neuropathy

CompletedNCT03943498

Mayo ClinicChemotherapy-Induced Peripheral Neuropathy, Numbness, Pain +1

Start: 2019-05-24End: 2020-12-10Updated: 2023-09-11

Phase 1

Fingolimod in Preventing Paclitaxel-Associated Neuropathy in Patients With Breast Cancer

CompletedNCT03941743

Mayo ClinicBreast Carcinoma

Start: 2019-12-12End: 2021-11-23Updated: 2023-07-21

Phase 3

A 2-year randomized, 3-arm, double-blind, non-inferiority study comparing the efficacy and safety of ofatumumab and siponimod versus fingolimod in pediatric patients with multiple sclerosis followed by an open-label extension

RecruitingCTIS2024-511686-11-00

Novartis Pharma AGMultiple Sclerosis in pediatric patients

Start: 2021-10-05Target: 64Updated: 2025-11-27